Market Research Logo

Portal Hypertension - Pipeline Review, H2 2016

Portal Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Portal Hypertension - Pipeline Review, H2 2016’, provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
    • The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
    • The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Portal Hypertension
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Portal Hypertension Overview
    Therapeutics Development
    Pipeline Products for Portal Hypertension - Overview
    Portal Hypertension - Therapeutics under Development by Companies
    Portal Hypertension - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Portal Hypertension - Products under Development by Companies
    Portal Hypertension - Companies Involved in Therapeutics Development
    Conatus Pharmaceuticals Inc.
    Cumberland Pharmaceuticals, Inc.
    Galectin Therapeutics, Inc.
    Genextra S.p.a.
    LinXis B.V.
    Mezzion Pharma Co. Ltd.
    Portal Hypertension - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    emricasan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRMD-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ifetroban sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LIN-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    obeticholic acid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    udenafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Portal Hypertension - Dormant Projects
    Portal Hypertension - Discontinued Products
    Portal Hypertension - Product Development Milestones
    Featured News & Press Releases
    Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
    ep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
    Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
    Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
    Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
    Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Portal Hypertension, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H2 2016
    Portal Hypertension - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
    Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016
    Portal Hypertension - Pipeline by Genextra S.p.a., H2 2016
    Portal Hypertension - Pipeline by LinXis B.V., H2 2016
    Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Portal Hypertension - Dormant Projects, H2 2016
    Portal Hypertension - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Portal Hypertension, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report